WO2013109210A1 - Dry powder formulations comprising budesonide - Google Patents

Dry powder formulations comprising budesonide Download PDF

Info

Publication number
WO2013109210A1
WO2013109210A1 PCT/TR2013/000022 TR2013000022W WO2013109210A1 WO 2013109210 A1 WO2013109210 A1 WO 2013109210A1 TR 2013000022 W TR2013000022 W TR 2013000022W WO 2013109210 A1 WO2013109210 A1 WO 2013109210A1
Authority
WO
WIPO (PCT)
Prior art keywords
range
pharmaceutical formulation
formulation according
excipient
particle size
Prior art date
Application number
PCT/TR2013/000022
Other languages
French (fr)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013109210A1 publication Critical patent/WO2013109210A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Definitions

  • the present invention relates to pharmaceutical formulations in dry powder form comprising budesonide or pharmaceutically acceptable derivatives thereof in order to be used in symptomatic and/or prophylactic treatment of respiratory tract diseases, particularly asthma and COPD.
  • Budesonide is used in the treatment of respiratory tract diseases such as asthma and COPD.
  • Budesonide which has the chemical name of 16,17-(butylidenebis(oxy))-l l,21-dihydroxy-, (l l-P,16-a)-pregna-l,4-diene-3,20-dione belongs to the group of corticosteroids.
  • Budesonide was first disclosed in the patent numbered US3929768.
  • Corticosteroids used in the treatment of respiratory tract diseases such as asthma and COPD are synthetic and potent anti-inflammatory drugs similar to natural corticosteroid hormones secreted by adrenal glands. It is known that corticosteroids are quite effective drugs in asthma treatment.
  • Budesonide is a molecule which belongs to said group.
  • the dry powder formulation comprising budesonide has good flow characteristics is an important criterion in terms of inhalation of said formulation effectively and therefore in terms of providing an effective treatment.
  • a dry powder formulation which does not have good flow characteristics is obtained, it is seen that the formulation has low homogeneity and consequently dosing accuracy cannot be ensured during filling the dry powder formulation prepared into reservoirs of multi dose inhalators comprising more than one dose or into blister cavities of a blister package, each of them comprising one dose, or into capsules comprising one dose.
  • the fact that the dry powder formulation does not have good flow characteristics affects emptying capacity and emptying attribute negatively during inhalation of the formulation from capsule, blister or reservoir.
  • the active agent cannot reach to the lungs in sufficient amounts.
  • the active agent is diluted by various non-functional excipients.
  • the physical characteristics of these excipients, used in quite high amounts as compared to the active agent amount in the formulations, such as average particle size have an important role in providing good flow in the dry powder formulation. Since the active agent used is delivered to the lungs in a sufficient amount and in a controlled manner in the dry powder formulation having good flow characteristics, desired therapeutic effect is obtained.
  • the inventors have developed dry powder formulations which comprise budesonide and/or pharmaceutically acceptable derivatives thereof and have high homogeneity and good flow characteristics wherein dosing accuracy is ensured and sufficient amount of active agent can be delivered to the lungs.
  • the present invention relates to pharmaceutical formulations in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof.
  • dry powder formulations comprising budesonide in the range of 25 to 650 ⁇ g, preferably in the range of 50 to 500 ⁇ g and also at least one pharmaceutically acceptable fine grained and coarse grained excipient having an average particle size ratio to each other in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 :15 to 1 :10 have good flow characteristics and high homogeneous dispersion, therefore dose accuracy is obtained in the formulations and sufficient amount of active agent can be delivered to the lungs.
  • the fine grained excipient used in the text refers to an excipient having an average particle size less than 10 ⁇ , preferably in the range of 0.1 to 9.9 ⁇ , more preferably in the range of 2 to 8 ⁇ , for instance in the range of 0.3, 0.5, 0.7, 0.9, 1.1, 1.3, 1.5, 1.7, 1.9, 2.3, 2.5, 3.0, 3.5, 4.0, 4.5 to 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 ⁇ ;
  • the coarse grained excipient used in the text refers to an excipient having an average particle size in the range of 10 to 90 ⁇ , preferably in the range of 12 to 85 ⁇ , more preferably in the range of 15 to 80 ⁇ , for instance in the range of 15, 20, 25, 30, 35, 40, 45 to 50, 55, 60, 65, 70, 75, 80, 85 ⁇ .
  • the subject of the present invention is the pharmaceutical formulation in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof, characterized in that the amount of budesonide in said formulation is in the range of 25 to 650 ⁇ g, preferably in the range of 50 to 500 g,
  • the excipient comprised in said formulation is composed of at least one pharmaceutically acceptable excipient mixture comprising fine grained excipient and coarse grained excipient and
  • the average particle size ratio of the fine grained excipient to the coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 : 15 to 1 :10.
  • the inhalation formulation comprising budesonide and/or pharmaceutically acceptable derivatives thereof can be delivered to the patient in dry powder form.
  • Said dry powder formulations further comprise at least one physiologically and pharmaceutically acceptable excipient along with the active agent.
  • This excipient is composed of fine grained excipient, coarse grained excipient or a combination thereof, preferably a combination of fine grained excipient and coarse grained excipient.
  • This excipient can be selected from monosaccharides (glucose etc.), disaccharides (lactose, saccharose, maltose or pharmaceutically acceptable hydrates, anhydrates or a combination thereof etc.), oligosaccharides and polysaccharides (dextrant etc.), polyalcohols (sorbitol, mannitol, xylitol etc.), salts (sodium chloride, calcium carbonate etc.) or a combination thereof. Same or different substances are used as fine grained excipient and coarse grained excipient, though preferably the same substance is used. Fine grained and coarse grained excipients are preferably lactose, more preferably lactose anhydrate. According to the present invention, the amount of the pharmaceutically acceptable excipient is preferably in the range of 1-50 mg, preferably in the range of 2-40 mg, more preferably in the range of 3-30 mg.
  • the average particle size of the active agent used is quite important in order that the formulation to be obtained has good flow characteristics and therefore an effective inhalation is performed.
  • the subject of the present invention is pharmaceutical formulations in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof, characterized in that
  • the amount of budesonide in said formulation is in the range of 25 to 650 ⁇ g, preferably in the range of 50 to 500 ⁇ g,
  • the average particle size ratio of fine grained excipient: coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 :15 to 1 :10 and
  • the average particle size of the active agent used is in the range of 1 ⁇ to 10 ⁇ , preferably in the range of 1.5 ⁇ to 7.5 ⁇ , more preferably in the range of 1.5 ⁇ to 5 ⁇ .
  • the particle size of the bulk formulation is also an important criteria for the flowability and dose uniformity of the formulation.
  • the inventors have seen that in the case that the average particle size (d50 value) of the bulk formulation is in the range of 10-100 ⁇ , preferably 20-90 ⁇ and more preferably 25-75 ⁇ , flowability of the bulk formulation is increased during the production and a homogeneous dry powder formulation which has a high dose uniformity is obtained.
  • the present invention relates to the pharmaceutical formulations in dry powder form comprising budesonid and/or pharmaceutically acceptable derivatives thereof wherein the average particle size (d50 value) of the bulk formulation is in the range of 10-100 ⁇ , preferably 20-90 ⁇ and more preferably 25- 75 ⁇ .
  • dlO and d90 values of the bulk formulation have also an influence on providing an appropriate flow and thus the dose uniformity of the formulation.
  • the inventors have observed that when the bulk formulation obtained during the production has dlO value in the range of 2-40 ⁇ , preferably 5- 30 ⁇ and has d90 value in the range of 60- 150 ⁇ , preferably 75- 125 ⁇ , the formulation has a high dose uniformity and a more effecient treatment can be provided.
  • the present invention relates to the pharmaceutical formulations in dry powder form comprising budesonid and/or pharmaceutically acceptable derivatives thereof wherein the bulk formulation obtained during the production has dlO value in the range of 2-40 ⁇ , preferably 5- 30 ⁇ and has d90 value in the range of 60- 150 ⁇ , preferably 75- 125 ⁇ .
  • the term bulk formulation used herein signifies that the total formulation obtained by mixing the active agent and the excipients during the production.
  • dlO used herein signifies that 10% of the formulation by volume has a particle size below the value stated with dlO.
  • dlO used herein signifies that 10% of the formulation by volume has a particle size below the value stated with d50.
  • d90 used herein signifies that 90% of the formulation by volume has a particle size below the value stated with d90.
  • the amounts of said fine grained and coarse grained excipients constituting the excipient combination having two different average particle sizes as fine grained and coarse grained comprised in the dry powder formulation of the present invention is an important criterion in obtaining the characteristics that can provide an effective treatment.
  • the inventors have seen that characteristics such as proper flow, particularly homogenous particle dispersion and dose uniformity of the formulation are ensured and therefore the sufficient amount of the active agent reaches to the lungs more easily in the case that the ratio of fine grained excipient to coarse grained excipient constituting the excipient combination is in the range of 1 :1 to 1 :25 by weight, preferably in the range of 1 :1 to 1 :10 by weight, more preferably in the range of 1 : 1.5 to 1 :5 by weight.
  • the subject of the present invention is the pharmaceutical formulations in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof, characterized in that
  • the amount of budesonide in said formulation is in the range of 25 to 650 ⁇ g, preferably in the range of 50 to 500 ⁇ g,
  • the average particle size ratio of fine grained excipient: coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 :15 to 1 : 10 and
  • the. ratio of fine grained excipient to coarse grained excipient is in the range of 1 : 1 to 1 :25 by weight, preferably in the range of 1 :1 to 1 :10 by weight, more preferably in the range of 1 : 1.5 to 1 :5 by weight. It is known that flowability is an important parameter for obtaining a homogeneous mixture of the active agent and the exc.ipients during the production and providing dose uniformity of the formulation and thus minimizing the amount of the active agent remained in the device. The parameters such as bulk density and tapped density have a considerable influence on providing good flowability.
  • the inventors have provided the dry powder formulation to have a good flowability by adjusting the bulk density and tapped density in the manner that the ratio of bulk density to tapped density is in the range of 1 :10 to 9.5:10, preferably 2:10 to 9:10, more preferably 3:10 to 9:10.
  • the present invention relates to the pharmaceutical formulations in dry powder form comprising budesonid and/or pharmaceutically acceptable derivatives thereof wherein the ratio of bulk density to tapped density is in the range of 1 :10 to 9.5:10, preferably 2: 10 to 9: 10, more preferably 3 : 10 to 9: 10.
  • the tapped density is obtained by compacting the bulk density with vibrational motion.
  • the present invention relates to inhalation of the dry powder formulations comprising budesonide and/or pharmaceutically acceptable derivatives thereof by using inhalation devices comprising capsule, blister or reservoir.
  • the inventors have found that the inhalation is performed most productively when capsule volume comprising the drug in dry powder form of the present invention comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 0.1 to 0.5 ml, preferably in the range of 0.15-0.45 ml, more preferably in the range of 0.2-0.4 ml.
  • the present invention is characterized in that volume of the capsule used for storage and delivery of the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 0.1 to 0.5 ml, preferably in the range of 0.15-0.45 ml, more preferably in the range of 0.2-0.4 ml.
  • the inventors have seen that the active agent comprised in the capsule is protected from external factors as well as the possibility of moistening that can arise from the nature of the capsule itself is removed in the case that moisture ratio of the package in capsule form having high protection property against moisture and other negative external factors is in the range of 5-20%, preferably in the range of 7-15%.
  • moisture ratio of the package in capsule form having high protection property against moisture and other negative external factors is in the range of 5-20%, preferably in the range of 7-15%.
  • the present invention is characterized in that moisture ratio of the package in capsule form used for storage and delivery of the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 5-20%, preferably in the range of 7-15%.
  • the capsule preferred to be used in the scope of the present invention can be made of a substance selected from a group comprising gelatine, chitosan, starch and/or starch derivatives, cellulose and/or cellulose derivatives or synthetic polymers, and it is composed of telescoping body and cap parts.
  • capsule material in the case that the dry powder formulation of the present invention is inhaled from capsule, capsule material can be selected from a group comprising hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose if the capsule to be used is made of cellulose and its derivatives.
  • capsule material can be selected from a group comprising polyethylene, , polyester, polyethyleneterephthalate, polycarbonate or polypropylene if the capsule to be used is made of synthetic polymer.
  • various molecular weighted polyethylene glycol, sorbitol, glycerol, propylene glycol, polyethylene oxide-propylene oxide block copolymers and/or other polyalcohols and polyethers can be added as adjuvant if the capsule material to be used is made of gelatine.
  • the inventors have found that in the case that fullness ratio of the capsule cavity used is in the range of 0.05 to 25 %, preferably in the range of 0.1 to 20%, more preferably in the range of 0.5-15%, an effective inhalation of the drug is ensured in the case that said dry powder formulation is inhaled from capsule.
  • the present invention is characterized in that fullness ratio of capsule cavity is in the range of 0.05 to 25%, preferably in the range of 0.1 to 20%, more preferably in the range of 0.5 to 15%.
  • the dry powder formulation of the present invention is inhaled from blister, which is one of the inhalation methods
  • the inventors have found that an effective inhalation is performed in the case that cavity volume of the blister comprising the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 18-30 mm 3 , preferably in the range of 20 - 25 mm 3 , more preferably in the range of 21-24 mm 3 .
  • the present invention is characterized in that cavity volume of the blister used for storage and delivery of the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is 18-30 mm 3 , preferably in the range of 20 to 25 mm , more preferably in the range of 21-24 mm in the case that said dry powder formulation is inhaled from blister.
  • fullness ratio of the blister cavity used should be in the range of 15-95%, preferably in the range of 20-85% and more preferably in the range of 50-80% in order to inhale the formulation of the present invention from blister without any problem and in order to perform an effective inhalation.
  • the present invention is characterized in that.fullnes.s ratio of the blister used for storage and delivery of the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 15-95%, preferably in the range of 20-85% and more preferably in the range of 50- 80%.
  • the base and the lid sheets constituting the peelable blister strip pack wherein the blisters comprising the dry powder formulation of the present invention are collocated, are sealed tightly by any suitable method in order to provide impermeability.
  • the base and lid sheets constituting the peelable blister strip package comprising the dry powder formulation of the present invention are composed of many layers. Polymeric layers, aluminium foil and preferably Aclar® fluoropolymer film are among the layers constituting the base and the lid sheets.
  • Desiccant agents added to the layers constituting blister strip package comprising dry powder formulation of the present invention are selected from silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated carbon, hydrophilic chyles.
  • polymeric layers in the base and lid sheets of peelable blister strip package comprising said dry powder formulation are made of the same or different polymers. Thickness of these polymeric layers varies depending on the type and characteristics of the polymeric material used. Therefore, thickness of the polymeric layer varies in the range of 15-55 ⁇ , preferably in the range of 20-30 ⁇ according to the type of the polymeric material used.
  • the layer covering the inner surface of the cavity is a polymeric layer because of the fact that when the layer in contact with the dry powder formulation in the blister cavity is aluminium foil, some part of dry powder formulation adheres to the inner surface of the blister cavity due to porous structure of the aluminium foil and electrostatic forces and this causes uncontrolled dose inhalation.
  • Polymers constituting the polymeric layer can preferably be selected from thermoplastic polymers such as polyethylene, polypropylene, polystyrene, polyolefin, polyamide, polyvinyl chloride, polyurethane or synthetic polymers.
  • the drug composition in dry powder form described in the present invention comprising budesonide and/or pharmaceutically acceptable derivatives thereof can be used in the treatment of many respiratory diseases particularly asthma, Chronic Obstructive Pulmonary Disease (COPD) and allergic rhinitis.
  • the drug composition of the present invention is used in the treatment of respiratory tract diseases comprising, but not limited to, allergic or non allergic asthma in every stage, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airways hyperactivity, chronic obstructive pulmonary disease including bronchiectasis, emphysema and chronic bronchitis; airways or lung diseases (COPD, COAD or COLD) pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.
  • This treatment may be prophylactic or symptomatic.
  • EXAMPLE 1 Inhalation of dry powder formulations comprising budesonide from capsule
  • fine grained lactose and coarse grained lactose are stirred in a mixer after sieved separately.
  • Budesonide is added into this mixture, sieved again and stirred.
  • the powder mixture obtained at the end of the process is filled into capsules.

Abstract

The present invention relates to pharmaceutical formulations in dry powder form comprising budesonide in order to be used in respiratory tract diseases.

Description

DRY POWDER FORMULATIONS COMPRISING BUDESONIDE
The present invention relates to pharmaceutical formulations in dry powder form comprising budesonide or pharmaceutically acceptable derivatives thereof in order to be used in symptomatic and/or prophylactic treatment of respiratory tract diseases, particularly asthma and COPD.
In case of respiratory tract diseases such as asthma or chronic obstructive pulmonary disease (COPD); stimulants such as allergen, infection, good and bad smell, smoke cause constricted muscles covering the airways, in other words bronchoconstriction, excessive secretion in glands and consequently contraction in the airways. In this case, the patient cannot exhale the inhaled air or he/she cannot inhale.
Budesonide is used in the treatment of respiratory tract diseases such as asthma and COPD. Budesonide which has the chemical name of 16,17-(butylidenebis(oxy))-l l,21-dihydroxy-, (l l-P,16-a)-pregna-l,4-diene-3,20-dione belongs to the group of corticosteroids. Budesonide was first disclosed in the patent numbered US3929768. Corticosteroids used in the treatment of respiratory tract diseases such as asthma and COPD are synthetic and potent anti-inflammatory drugs similar to natural corticosteroid hormones secreted by adrenal glands. It is known that corticosteroids are quite effective drugs in asthma treatment. Budesonide is a molecule which belongs to said group.
The fact that the dry powder formulation comprising budesonide has good flow characteristics is an important criterion in terms of inhalation of said formulation effectively and therefore in terms of providing an effective treatment. In the case that a dry powder formulation which does not have good flow characteristics is obtained, it is seen that the formulation has low homogeneity and consequently dosing accuracy cannot be ensured during filling the dry powder formulation prepared into reservoirs of multi dose inhalators comprising more than one dose or into blister cavities of a blister package, each of them comprising one dose, or into capsules comprising one dose. Furthermore, the fact that the dry powder formulation does not have good flow characteristics affects emptying capacity and emptying attribute negatively during inhalation of the formulation from capsule, blister or reservoir. As a result, due to the reasons listed above, the active agent cannot reach to the lungs in sufficient amounts. In order to ease the delivery of the active agent having therapeutic effect in quite small doses by the inhalation route, the active agent is diluted by various non-functional excipients. The physical characteristics of these excipients, used in quite high amounts as compared to the active agent amount in the formulations, such as average particle size have an important role in providing good flow in the dry powder formulation. Since the active agent used is delivered to the lungs in a sufficient amount and in a controlled manner in the dry powder formulation having good flow characteristics, desired therapeutic effect is obtained.
The inventors have developed dry powder formulations which comprise budesonide and/or pharmaceutically acceptable derivatives thereof and have high homogeneity and good flow characteristics wherein dosing accuracy is ensured and sufficient amount of active agent can be delivered to the lungs.
Description of the Invention
The present invention relates to pharmaceutical formulations in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof. Surprisingly, the inventors have seen that dry powder formulations comprising budesonide in the range of 25 to 650 μg, preferably in the range of 50 to 500 μg and also at least one pharmaceutically acceptable fine grained and coarse grained excipient having an average particle size ratio to each other in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 :15 to 1 :10 have good flow characteristics and high homogeneous dispersion, therefore dose accuracy is obtained in the formulations and sufficient amount of active agent can be delivered to the lungs.
The fine grained excipient used in the text refers to an excipient having an average particle size less than 10 μιη, preferably in the range of 0.1 to 9.9 μπι, more preferably in the range of 2 to 8 μιη, for instance in the range of 0.3, 0.5, 0.7, 0.9, 1.1, 1.3, 1.5, 1.7, 1.9, 2.3, 2.5, 3.0, 3.5, 4.0, 4.5 to 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 μηι; the coarse grained excipient used in the text refers to an excipient having an average particle size in the range of 10 to 90 μιτι, preferably in the range of 12 to 85 μπι, more preferably in the range of 15 to 80 μιη, for instance in the range of 15, 20, 25, 30, 35, 40, 45 to 50, 55, 60, 65, 70, 75, 80, 85 μπι.
According to this, the subject of the present invention is the pharmaceutical formulation in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof, characterized in that the amount of budesonide in said formulation is in the range of 25 to 650 μg, preferably in the range of 50 to 500 g,
- the excipient comprised in said formulation is composed of at least one pharmaceutically acceptable excipient mixture comprising fine grained excipient and coarse grained excipient and
- the average particle size ratio of the fine grained excipient to the coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 : 15 to 1 :10.
According to the present invention, the inhalation formulation comprising budesonide and/or pharmaceutically acceptable derivatives thereof can be delivered to the patient in dry powder form. Said dry powder formulations further comprise at least one physiologically and pharmaceutically acceptable excipient along with the active agent. This excipient is composed of fine grained excipient, coarse grained excipient or a combination thereof, preferably a combination of fine grained excipient and coarse grained excipient. This excipient can be selected from monosaccharides (glucose etc.), disaccharides (lactose, saccharose, maltose or pharmaceutically acceptable hydrates, anhydrates or a combination thereof etc.), oligosaccharides and polysaccharides (dextrant etc.), polyalcohols (sorbitol, mannitol, xylitol etc.), salts (sodium chloride, calcium carbonate etc.) or a combination thereof. Same or different substances are used as fine grained excipient and coarse grained excipient, though preferably the same substance is used. Fine grained and coarse grained excipients are preferably lactose, more preferably lactose anhydrate. According to the present invention, the amount of the pharmaceutically acceptable excipient is preferably in the range of 1-50 mg, preferably in the range of 2-40 mg, more preferably in the range of 3-30 mg.
On the other hand, along with the particle size of the excipient comprised in the dry powder formulations of the present invention, the average particle size of the active agent used is quite important in order that the formulation to be obtained has good flow characteristics and therefore an effective inhalation is performed.
The inventors have seen that use of an active agent having an average particle size in the range of 1 μηι to 10 μπι, preferably in the range of 1.5 μιη to 7.5 μιη, more preferably in the range of 1.5 μηι to 5 μηι has a significant contribution to the formulation obtained for having proper flow characteristics and for having dose uniformity and to delivery of the active agent to the lungs in sufficient amount. > According to this, the subject of the present invention is pharmaceutical formulations in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof, characterized in that
- the amount of budesonide in said formulation is in the range of 25 to 650 μg, preferably in the range of 50 to 500 μg,
- the average particle size ratio of fine grained excipient: coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 :15 to 1 :10 and
- the average particle size of the active agent used is in the range of 1 μπι to 10 μπι, preferably in the range of 1.5 μιη to 7.5 μηι, more preferably in the range of 1.5 μπι to 5 μηι.
In addition to the average particle size of the active agent, the particle size of the bulk formulation is also an important criteria for the flowability and dose uniformity of the formulation. The inventors have seen that in the case that the average particle size (d50 value) of the bulk formulation is in the range of 10-100 μηι, preferably 20-90 μηι and more preferably 25-75 μηι, flowability of the bulk formulation is increased during the production and a homogeneous dry powder formulation which has a high dose uniformity is obtained.
In another aspect, the present invention relates to the pharmaceutical formulations in dry powder form comprising budesonid and/or pharmaceutically acceptable derivatives thereof wherein the average particle size (d50 value) of the bulk formulation is in the range of 10-100 μηι, preferably 20-90 μηι and more preferably 25- 75 μηι.
It is seen that dlO and d90 values of the bulk formulation have also an influence on providing an appropriate flow and thus the dose uniformity of the formulation. The inventors have observed that when the bulk formulation obtained during the production has dlO value in the range of 2-40 μηι, preferably 5- 30 μηι and has d90 value in the range of 60- 150 μπι, preferably 75- 125 μιη, the formulation has a high dose uniformity and a more effecient treatment can be provided.
In another aspect, the present invention relates to the pharmaceutical formulations in dry powder form comprising budesonid and/or pharmaceutically acceptable derivatives thereof wherein the bulk formulation obtained during the production has dlO value in the range of 2-40 μηι, preferably 5- 30 μιη and has d90 value in the range of 60- 150 μπι, preferably 75- 125 μηι. v The term bulk formulation used herein signifies that the total formulation obtained by mixing the active agent and the excipients during the production.
The term dlO used herein signifies that 10% of the formulation by volume has a particle size below the value stated with dlO. The term dlO used herein signifies that 10% of the formulation by volume has a particle size below the value stated with d50.
The term d90 used herein signifies that 90% of the formulation by volume has a particle size below the value stated with d90.
The amounts of said fine grained and coarse grained excipients constituting the excipient combination having two different average particle sizes as fine grained and coarse grained comprised in the dry powder formulation of the present invention is an important criterion in obtaining the characteristics that can provide an effective treatment. The inventors have seen that characteristics such as proper flow, particularly homogenous particle dispersion and dose uniformity of the formulation are ensured and therefore the sufficient amount of the active agent reaches to the lungs more easily in the case that the ratio of fine grained excipient to coarse grained excipient constituting the excipient combination is in the range of 1 :1 to 1 :25 by weight, preferably in the range of 1 :1 to 1 :10 by weight, more preferably in the range of 1 : 1.5 to 1 :5 by weight.
In another aspect, the subject of the present invention is the pharmaceutical formulations in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof, characterized in that
- the amount of budesonide in said formulation is in the range of 25 to 650 μg, preferably in the range of 50 to 500 μg,
- the average particle size ratio of fine grained excipient: coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 :15 to 1 : 10 and
- the. ratio of fine grained excipient to coarse grained excipient is in the range of 1 : 1 to 1 :25 by weight, preferably in the range of 1 :1 to 1 :10 by weight, more preferably in the range of 1 : 1.5 to 1 :5 by weight. It is known that flowability is an important parameter for obtaining a homogeneous mixture of the active agent and the exc.ipients during the production and providing dose uniformity of the formulation and thus minimizing the amount of the active agent remained in the device. The parameters such as bulk density and tapped density have a considerable influence on providing good flowability. The inventors have provided the dry powder formulation to have a good flowability by adjusting the bulk density and tapped density in the manner that the ratio of bulk density to tapped density is in the range of 1 :10 to 9.5:10, preferably 2:10 to 9:10, more preferably 3:10 to 9:10.
In another aspect, the present invention relates to the pharmaceutical formulations in dry powder form comprising budesonid and/or pharmaceutically acceptable derivatives thereof wherein the ratio of bulk density to tapped density is in the range of 1 :10 to 9.5:10, preferably 2: 10 to 9: 10, more preferably 3 : 10 to 9: 10.
The tapped density is obtained by compacting the bulk density with vibrational motion.
The process for preparation of the pharmaceutical formulations of the present invention in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is composed of the following steps:
I. micronizing budesonide so as to bring it to the desired particle size,
II. micronizing the excipient so as to bring it to the desired particle size,
III. mixing the active agent micronized in the Ist step firstly with the fine grained excipient and then the coarse grained excipient in a mixer or firstly with the coarse grained excipient and then the fine grained excipient in a mixer and
IV. consequently, filling the mixture obtained in dry powder form into appropriate capsules, blisters or reservoirs and making it ready for use.
In another aspect, the present invention relates to inhalation of the dry powder formulations comprising budesonide and/or pharmaceutically acceptable derivatives thereof by using inhalation devices comprising capsule, blister or reservoir.
In the case that the dry powder formulation of the present invention is inhaled from capsule, which is one of the inhalation methods, the inventors have found that the inhalation is performed most productively when capsule volume comprising the drug in dry powder form of the present invention comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 0.1 to 0.5 ml, preferably in the range of 0.15-0.45 ml, more preferably in the range of 0.2-0.4 ml.
According to this, in the case that the dry powder formulation of the present invention is inhaled from capsule, the present invention is characterized in that volume of the capsule used for storage and delivery of the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 0.1 to 0.5 ml, preferably in the range of 0.15-0.45 ml, more preferably in the range of 0.2-0.4 ml.
In another aspect, the inventors have seen that the active agent comprised in the capsule is protected from external factors as well as the possibility of moistening that can arise from the nature of the capsule itself is removed in the case that moisture ratio of the package in capsule form having high protection property against moisture and other negative external factors is in the range of 5-20%, preferably in the range of 7-15%. Thus, effective delivery of the formulation in dry powder form of the present invention to the lungs of the patient is enabled by preventing agglomeration. According to this, in the case that the dry powder formulation of the present invention is inhaled from capsule, the present invention is characterized in that moisture ratio of the package in capsule form used for storage and delivery of the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 5-20%, preferably in the range of 7-15%. In another aspect, in the case that the dry powder formulation of the present invention is inhaled from capsule, the capsule preferred to be used in the scope of the present invention can be made of a substance selected from a group comprising gelatine, chitosan, starch and/or starch derivatives, cellulose and/or cellulose derivatives or synthetic polymers, and it is composed of telescoping body and cap parts. According to this, in the case that the dry powder formulation of the present invention is inhaled from capsule, capsule material can be selected from a group comprising hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose if the capsule to be used is made of cellulose and its derivatives. In the case that the dry powder formulation of the present invention is inhaled from capsule, capsule material can be selected from a group comprising polyethylene, , polyester, polyethyleneterephthalate, polycarbonate or polypropylene if the capsule to be used is made of synthetic polymer.
In the case that the dry powder formulation of the present invention is inhaled from capsule, various molecular weighted polyethylene glycol, sorbitol, glycerol, propylene glycol, polyethylene oxide-propylene oxide block copolymers and/or other polyalcohols and polyethers can be added as adjuvant if the capsule material to be used is made of gelatine.
In another aspect, the inventors have found that in the case that fullness ratio of the capsule cavity used is in the range of 0.05 to 25 %, preferably in the range of 0.1 to 20%, more preferably in the range of 0.5-15%, an effective inhalation of the drug is ensured in the case that said dry powder formulation is inhaled from capsule.
According to this, in the case that said dry powder formulation is inhaled from capsule, the present invention is characterized in that fullness ratio of capsule cavity is in the range of 0.05 to 25%, preferably in the range of 0.1 to 20%, more preferably in the range of 0.5 to 15%.
In the case that the dry powder formulation of the present invention is inhaled from blister, which is one of the inhalation methods, the inventors have found that an effective inhalation is performed in the case that cavity volume of the blister comprising the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 18-30 mm3, preferably in the range of 20 - 25 mm3, more preferably in the range of 21-24 mm3.
According to this, the present invention is characterized in that cavity volume of the blister used for storage and delivery of the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is 18-30 mm3, preferably in the range of 20 to 25 mm , more preferably in the range of 21-24 mm in the case that said dry powder formulation is inhaled from blister.
The inventors have found that fullness ratio of the blister cavity used should be in the range of 15-95%, preferably in the range of 20-85% and more preferably in the range of 50-80% in order to inhale the formulation of the present invention from blister without any problem and in order to perform an effective inhalation. , In the case that said dry powder formulation is inhaled from blister, the present invention is characterized in that.fullnes.s ratio of the blister used for storage and delivery of the drug in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof is in the range of 15-95%, preferably in the range of 20-85% and more preferably in the range of 50- 80%.
In the case that the dry powder formulation of the present invention is inhaled from blister, the base and the lid sheets constituting the peelable blister strip pack, wherein the blisters comprising the dry powder formulation of the present invention are collocated, are sealed tightly by any suitable method in order to provide impermeability. The base and lid sheets constituting the peelable blister strip package comprising the dry powder formulation of the present invention are composed of many layers. Polymeric layers, aluminium foil and preferably Aclar® fluoropolymer film are among the layers constituting the base and the lid sheets.
The inventors have seen that, in the case that the formulation of the present invention is inhaled from blister, adding desiccant to the polymeric layers in order to reduce moisture and gas permeability of base and lid sheets constituting the blister package is effective in protecting stability of said dry powder formulation. Desiccant agents added to the layers constituting blister strip package comprising dry powder formulation of the present invention are selected from silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated carbon, hydrophilic chyles.
In the case that dry powder formulation of the present invention is inhaled from blister, polymeric layers in the base and lid sheets of peelable blister strip package comprising said dry powder formulation are made of the same or different polymers. Thickness of these polymeric layers varies depending on the type and characteristics of the polymeric material used. Therefore, thickness of the polymeric layer varies in the range of 15-55 μιη, preferably in the range of 20-30 μηι according to the type of the polymeric material used.
The layer covering the inner surface of the cavity is a polymeric layer because of the fact that when the layer in contact with the dry powder formulation in the blister cavity is aluminium foil, some part of dry powder formulation adheres to the inner surface of the blister cavity due to porous structure of the aluminium foil and electrostatic forces and this causes uncontrolled dose inhalation. Polymers constituting the polymeric layer can preferably be selected from thermoplastic polymers such as polyethylene, polypropylene, polystyrene, polyolefin, polyamide, polyvinyl chloride, polyurethane or synthetic polymers. The drug composition in dry powder form described in the present invention comprising budesonide and/or pharmaceutically acceptable derivatives thereof can be used in the treatment of many respiratory diseases particularly asthma, Chronic Obstructive Pulmonary Disease (COPD) and allergic rhinitis. Accordingly, the drug composition of the present invention is used in the treatment of respiratory tract diseases comprising, but not limited to, allergic or non allergic asthma in every stage, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airways hyperactivity, chronic obstructive pulmonary disease including bronchiectasis, emphysema and chronic bronchitis; airways or lung diseases (COPD, COAD or COLD) pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis. This treatment may be prophylactic or symptomatic. In addition, the composition of the present invention is particularly used in symptomatic treatment of asthma, allergic rhinitis and COPD.
EXAMPLE 1 : Inhalation of dry powder formulations comprising budesonide from capsule
Figure imgf000011_0001
In obtainment of the formulation that shall be used in said invention, fine grained lactose and coarse grained lactose are stirred in a mixer after sieved separately. Budesonide is added into this mixture, sieved again and stirred. The powder mixture obtained at the end of the process is filled into capsules. EXAMPLE 2: Inhalation of dry powder formulations comprising budesonide from capsule
Figure imgf000012_0001
In obtainment of the formulation that shall be used in said invention, fine grained lactose and coarse grained lactose are stirred in a mixer after sieved separately. Budesonide is added into this mixture, sieved again and stirred. The powder mixture obtained at the end of the process is filled into capsules.

Claims

1. A pharmaceutical formulation in dry powder form comprising budesonide and/or pharmaceutically acceptable derivatives thereof, characterized in that
the amount of budesonide in the formulation is in the range of 25 to 650 μg, - the excipient comprised in said formulation is composed of an excipient combination comprising a fine grained excipient having an average particle size less than 10 μπι and a coarse grained excipient having an average particle size in the range of 10 μηι to 90 μηι and
the average particle size ratio of the fine grained excipient: the coarse grained excipient is in the range of 1 :30 to 1 :2.
2. The pharmaceutical formulation according to claim 1, characterized in that the amount of budesonide in the formulation is in the range of 50 to 500 μg.
3. The pharmaceutical formulation according to claims 1-2, characterized in that the average particle size ratio of fine grained excipient: coarse grained excipient is in the range of 1 :20 to 1 :5.
4. The pharmaceutical formulation according to claims 1-3, characterized in that the average particle size ratio of fine grained excipient: coarse grained excipient is in the range of 1 : 15 to 1 :10.
5. The pharmaceutical formulation according to claims 1-4, characterized in that the average particle size of the fine grained excipient is in the range of 0.1 to 9.9 μπι.
6. The pharmaceutical formulation according to claims 1-5, characterized in that the average particle size of the fine grained excipient is in the range of 2 to 8 μηι.
7. The pharmaceutical formulation according to claims 1-6, characterized in that the average particle size of the fine grained excipient is in the range of 0.3, 0.5, 0.7, 0.9, 1.1, 1.3, 1.5, 1.7, 1.9, 2.3, 2.5, 3.0, 3.5, 4.0, 4.5 to 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 μιη.
8. The pharmaceutical formulation according to claims 1-7, characterized in that the average particle size of the coarse grained excipient is in the range of 12 to 85 μιη.
9. The pharmaceutical formulation according to claims 1-8, characterized in that the average particle size of the coarse grained excipient is in the range of 15 to 80 μιη.
10. The pharmaceutical formulation according to claims 1-9, characterized in that the average particle size of the coarse grained excipient is in the range of 20, 25, 30, 35, 40, 45 to 50, 55, 60, 65, 70, 75, 80, 85 μιη.
1 1. The pharmaceutical formulation according claims 1-10, wherein budesonide and/or pharmaceutically acceptable derivatives thereof comprise its free base, pharmaceutically acceptable solvates, hydrates, enantiomers or diastereomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms and/or a combination thereof.
12. The pharmaceutical formulation according to claims 1-1 1, wherein the fine grained and the coarse grained excipients are selected from monosaccharides (glucose), disaccharides (lactose, saccharose, maltose or pharmaceutically acceptable hydrates, solvates, anhydrous forms or a combination thereof), oligosaccharides and polysaccharides (dextrant), polyalcohols (sorbitol, mannitol, xylitol), salts (sodium chloride, calcium carbonate) or a combination thereof.
13. The pharmaceutical formulation according to claims 1-12, wherein the fine grained and the coarse grained excipients are selected from the same or different substances.
14. The pharmaceutical formulation according to claims 1-13, wherein lactose or a pharmaceutically acceptable hydrate, anhydrate or a combination thereof is used as fine grained excipient and coarse grained excipient.
15. The pharmaceutical formulation according to claims 12-14, wherein lactose anhydrate is used as fine grained excipient and coarse grained excipient.
16. The pharmaceutical formulation according to claims 1-15, wherein the total amount of the pharmaceutically acceptable excipient is in the range of 1-50 mg.
17. The pharmaceutical formulation according to claim 16, wherein the total amount of the pharmaceutically acceptable excipient is in the range of 2-40 mg.
18. The pharmaceutical formulation according to claim 17, wherein the total amount of the pharmaceutically acceptable excipient is in the range of 3-30 mg.
19. The pharmaceutical formulation according to claims 1-18, wherein the average particle size of the active agent comprised in said formulation is in the range of 1 μηι to 10 μηι.
20. The pharmaceutical formulation according to claim 19, wherein the average particle size of the active agent comprised in said formulation is in the range of 1.5 μηι to 7.5 μιη.
21. The pharmaceutical formulation according to claim 20, wherein the average particle size of the active agent comprised in said formulation is particularly in the range of 1.5 μηι to 5 μιυ.
22. The pharmaceutical formulation according to claims 1- 21 wherein the average particle size (d50 value) of bulk formulation is in the range of 10-100 μηι.
23. The pharmaceutical formulation according to claim 22 wherein the average particle size (d50 value) of the bulk formulation is in the range of 20-90 μπι.
24. The pharmaceutical formulation according to claim 22- 23 wherein the average particle size (d50 value) of the bulk formulation is in the range of 25- 75 μιη.
25. The pharmaceutical formulation according to claims 1- 24 wherein bulk formulation obtained during the production has dlO value in the range of 2-40 μπι and has d90 value in the range of 60- 150 μιη.
26. The pharmaceutical formulation according to claim 25 wherein the bulk formulation obtained during the production has dlO value in the range of 5- 30 μιη and has d90 value in the range of 75- 125 μπι.
27. The pharmaceutical formulation according to claims 1-21, wherein the ratio of fine grained excipient to coarse grained excipient is in the range of 1 : 1 to 1 :25 by weight.
28. The pharmaceutical formulation according to claim 22, wherein the ratio of fine grained excipient to coarse grained excipient is in the range of 1 : 1 to 1 : 10 by weight.
29. The pharmaceutical formulation according to claim 23, wherein the ratio of fine grained excipient to coarse grained excipient is in the range of 1 : 1.5 to 1 :5 by weight.
30. The pharmaceutical formulation according to claims 1- 29 wherein ratio of bulk density to tapped density is in the range of 1 : 10 to 9.5:10.
31. The pharmaceutical formulation according to claim 30 wherein the ratio of bulk density to tapped density is in the range of 2 : 10 to 9 : 10.
32. The pharmaceutical formulation according to claims 30- 31 wherein the ratio of bulk density to tapped density is in the range of 3:10 to 9:10.
33. A process for preparation of the pharmaceutical formulation according to claims 1-24, characterized in that said process is composed of the steps of:
I. micronizing budesonide so as to bring it to the desired particle size,
II. micronizing the excipients together or separately in order to bring them to the desired particle size,
III. mixing the active agent micronized in step I firstly with the fine grained excipient and then with the coarse grained excipient in a mixer or firstly with the coarse grained excipient and then with the fine grained excipient in a mixer and
IV. consequently, filling the mixture obtained in dry powder form into suitable, capsules, blisters or reservoirs and making it ready for use.
PCT/TR2013/000022 2012-01-16 2013-01-16 Dry powder formulations comprising budesonide WO2013109210A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/00486 2012-01-16
TR201200486 2012-01-16

Publications (1)

Publication Number Publication Date
WO2013109210A1 true WO2013109210A1 (en) 2013-07-25

Family

ID=47913532

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2013/000026 WO2013109214A1 (en) 2012-01-16 2013-01-16 Process for the preparation of dry powder formulations
PCT/TR2013/000022 WO2013109210A1 (en) 2012-01-16 2013-01-16 Dry powder formulations comprising budesonide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000026 WO2013109214A1 (en) 2012-01-16 2013-01-16 Process for the preparation of dry powder formulations

Country Status (1)

Country Link
WO (2) WO2013109214A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020013793A3 (en) * 2018-07-12 2020-02-20 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising dopamine agonists
WO2020055357A3 (en) * 2018-08-10 2020-04-16 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising phosphodiesterase-4 inhibitor
WO2020055356A3 (en) * 2018-07-20 2020-05-14 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising anti-bacterial agents

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776208T3 (en) 2015-12-03 2020-07-29 Tiefenbacher Alfred E Gmbh & Co Kg Dry powder mixing procedure

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929768A (en) 1972-05-19 1975-12-30 Bofors Ab Steroids, processes for their manufacture and preparations containing same
US20030180227A1 (en) * 2000-04-17 2003-09-25 Staniforth John Nicholas Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
WO2011093812A2 (en) * 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011093817A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising tiotropium, formoterol and budesonide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929768A (en) 1972-05-19 1975-12-30 Bofors Ab Steroids, processes for their manufacture and preparations containing same
US20030180227A1 (en) * 2000-04-17 2003-09-25 Staniforth John Nicholas Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
WO2011093812A2 (en) * 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011093817A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising tiotropium, formoterol and budesonide

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020013793A3 (en) * 2018-07-12 2020-02-20 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising dopamine agonists
WO2020055356A3 (en) * 2018-07-20 2020-05-14 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising anti-bacterial agents
WO2020055357A3 (en) * 2018-08-10 2020-04-16 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising phosphodiesterase-4 inhibitor

Also Published As

Publication number Publication date
WO2013109214A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
EP2528585B1 (en) Pharmaceutical compositions comprising tiotropium, formoterol and budesonide
EP2528596B1 (en) Dry powder formulations administered by the inhalation route comprising a combination of tiotropium bromide, salmeterol xynafoate and fluticasone propionate.
EP2533777B1 (en) Pharmaceutical compositions comprising fluticasone, tiotropium and sodium cromoglycate
EP2528600B1 (en) Dry powder pharmaceutical composition comprising tiotropium and fluticasone
WO2011093819A2 (en) New combination comprising tiotropium
WO2011093820A2 (en) A pharmaceutical combination comprising tiotropium
WO2013109210A1 (en) Dry powder formulations comprising budesonide
WO2013109220A1 (en) Dry powder formulations comprising tiotropium, formoterol and budesonide
EP2804590A1 (en) Dry powder formulations comprising tiotropium and carmoterol
WO2013009271A1 (en) New improved dry powder formulation
EP2480203B1 (en) Dry powder formulation of tiotropium carried in blister strip
WO2013109218A1 (en) Dry powder formulations comprising carmoterol and ciclesonide
EP2804589A1 (en) Pharmaceutical formulations comprising aztreonam
WO2011093811A2 (en) Pharmaceutical preparations comprising formoterol and fluticasone
EP2528597B1 (en) Dry powder formulation comprising a pharmaceutical combination of tiotropium bromide, formoterol fumarate and mometasone furoate
WO2013109209A1 (en) Dry powder formulations comprising fluticasone
WO2013109212A1 (en) Dry powder formulations comprising ciclesonide
WO2013109207A1 (en) Dry powder formulations comprising mometasone
EP2515888B1 (en) Dry powder formulation containing tiotropium for inhalation
WO2013109213A2 (en) Pharmaceutical formulations comprising tiotropium
WO2013109208A1 (en) Formulations comprising formoterol as active agent
EP2804583A1 (en) Dry powder formulations comprising r-formoterol as active agent
WO2011093812A2 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
EP2480202A2 (en) Carrying of a combination containing tiotropium in a blister strip
WO2011078816A1 (en) Dry powder combination of tiotropium, formoterol and a cromoglicic acid derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13711159

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13711159

Country of ref document: EP

Kind code of ref document: A1